Endocyte (NASDAQ: ECYT) has partnered with pharma powerhouse Merck (NYSE: MRK) to develop its experimental drug vintafolide, a compound with orphan drug status in Europe that's used to treat a specific type of ovarian cancer. The companies submitted their official application for the approval of vintafolide to the European Medicines Agency (EMA) today.
As this drug goes under review, health-care analysts Max Macaluso and Brenton Flynn discuss the details of this partnership and another cancer drug for which Merck is seeking approval along with biotech Ariad (Nasdaq: ARIA).
Brenton Flynn, Max Macaluso, Ph.D., and The Motley Fool have no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
What Happened in the Stock Market Today
On a day stocks bounced up and down, shares of Energizer Holdings rose on acquisition news, and Merck reported positive results in a lung cancer trial.
These 3 Dividend Giants Are Safer Than You Think
Concerns about these stocks and their dividends are overblown.
Why 2017 Was a Year to Forget for Merck & Co. Inc.
Everything looked OK for the drugmaker until Merck delivered an unwelcome October surprise.